SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?

Описание к видео SGLT2 Inhibitors: Can these drugs slow the progression of chronic kidney disease?

By Vivian Jan Tarkul, Pharm.D, MS and Patrick Cunningham Ahearn, MD MAS. Held on October 23, 2022. This webinar covers the results of the CREDENCE Trial and DAPA-CKD Trial and the drugs canagliflozin and dapagliflozin and their effects on chronic kidney disease.

Комментарии

Информация по комментариям в разработке